258 related articles for article (PubMed ID: 26515688)
21. Squamosamide derivative FLZ protected tyrosine hydroxylase function in a chronic MPTP/probenecid mouse model of Parkinson's disease.
Bao XQ; Wu LY; Wang XL; Sun H; Zhang D
Naunyn Schmiedebergs Arch Pharmacol; 2015 May; 388(5):549-56. PubMed ID: 25678053
[TBL] [Abstract][Full Text] [Related]
22. Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease.
Pan J; Xiao Q; Sheng CY; Hong Z; Yang HQ; Wang G; Ding JQ; Chen SD
Neurochem Int; 2009 Jun; 54(7):418-25. PubMed ID: 19428783
[TBL] [Abstract][Full Text] [Related]
23. Activation of the ATF2/CREB-PGC-1α pathway by metformin leads to dopaminergic neuroprotection.
Kang H; Khang R; Ham S; Jeong GR; Kim H; Jo M; Lee BD; Lee YI; Jo A; Park C; Kim H; Seo J; Paek SH; Lee YS; Choi JY; Lee Y; Shin JH
Oncotarget; 2017 Jul; 8(30):48603-48618. PubMed ID: 28611284
[TBL] [Abstract][Full Text] [Related]
24. Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease.
Castro-Caldas M; Carvalho AN; Rodrigues E; Henderson CJ; Wolf CR; Rodrigues CM; Gama MJ
Mol Neurobiol; 2012 Oct; 46(2):475-86. PubMed ID: 22773138
[TBL] [Abstract][Full Text] [Related]
25. Microglial activation and age-related dopaminergic neurodegeneration in MPTP-treated SAMP8 mice.
Liu J; Wang MW; Gu P; Ma QY; Wang YY; Geng Y; Yuan ZY; Cui DS; Zhang ZX; Ma L; Zhang BH; Zhou MG; Zhu AP
Brain Res; 2010 Jul; 1345():213-20. PubMed ID: 20546706
[TBL] [Abstract][Full Text] [Related]
26. JNK-mediated microglial DICER degradation potentiates inflammatory responses to induce dopaminergic neuron loss.
Wang Q; He Q; Chen Y; Shao W; Yuan C; Wang Y
J Neuroinflammation; 2018 Jun; 15(1):184. PubMed ID: 29907159
[TBL] [Abstract][Full Text] [Related]
27. Effect of Zishenpingchan granule prepared from Chinese medicinal substances on the c-Jun N-terminal protein kinase pathway in mice with Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Ye Q; Yuan X; Zhou J; Yuan C; Yang X
J Tradit Chin Med; 2017 Apr; 37(2):244-51. PubMed ID: 29960635
[TBL] [Abstract][Full Text] [Related]
28. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
[TBL] [Abstract][Full Text] [Related]
29. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.
Choi DY; Lee MK; Hong JT
Neurobiol Dis; 2013 Jan; 49():159-68. PubMed ID: 22922220
[TBL] [Abstract][Full Text] [Related]
30. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease.
Hunot S; Vila M; Teismann P; Davis RJ; Hirsch EC; Przedborski S; Rakic P; Flavell RA
Proc Natl Acad Sci U S A; 2004 Jan; 101(2):665-70. PubMed ID: 14704277
[TBL] [Abstract][Full Text] [Related]
31. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease.
Tian YM; Chen X; Luo DZ; Zhang XH; Xue H; Zheng LF; Yang N; Wang XM; Zhu JX
Neuroscience; 2008 May; 153(3):634-44. PubMed ID: 18420351
[TBL] [Abstract][Full Text] [Related]
32. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
Sconce MD; Churchill MJ; Greene RE; Meshul CK
Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
[TBL] [Abstract][Full Text] [Related]
33. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo.
Saporito MS; Thomas BA; Scott RW
J Neurochem; 2000 Sep; 75(3):1200-8. PubMed ID: 10936203
[TBL] [Abstract][Full Text] [Related]
34. Activation of the c-Jun N terminal kinase pathway in an animal model of Parkinson's disease.
Willesen MG; Gammeltoft S; Vaudano E
Ann N Y Acad Sci; 2002 Nov; 973():237-40. PubMed ID: 12485868
[TBL] [Abstract][Full Text] [Related]
35. Toxicity of MPTP on neurotransmission in three mouse models of Parkinson's disease.
Pain S; Gochard A; Bodard S; Gulhan Z; Prunier-Aesch C; Chalon S
Exp Toxicol Pathol; 2013 Jul; 65(5):689-94. PubMed ID: 23083629
[TBL] [Abstract][Full Text] [Related]
36. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
Meuer K; Pitzer C; Teismann P; Krüger C; Göricke B; Laage R; Lingor P; Peters K; Schlachetzki JC; Kobayashi K; Dietz GP; Weber D; Ferger B; Schäbitz WR; Bach A; Schulz JB; Bähr M; Schneider A; Weishaupt JH
J Neurochem; 2006 May; 97(3):675-86. PubMed ID: 16573658
[TBL] [Abstract][Full Text] [Related]
37. Harpagoside attenuates MPTP/MPP⁺ induced dopaminergic neurodegeneration and movement disorder via elevating glial cell line-derived neurotrophic factor.
Sun X; Xiong Z; Zhang Y; Meng Y; Xu G; Xia Z; Li J; Zhang R; Ke Z; Xia Z; Hu Y
J Neurochem; 2012 Mar; 120(6):1072-83. PubMed ID: 22192054
[TBL] [Abstract][Full Text] [Related]
38. Shikonin ameliorates oxidative stress and neuroinflammation via the Akt/ERK/JNK/NF-κB signalling pathways in a model of Parkinson's disease.
Guo L; Li Y; Li W; Qiu J; Du J; Wang L; Zhang T
Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1221-1231. PubMed ID: 36054693
[TBL] [Abstract][Full Text] [Related]
39. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
Tasaki Y; Yamamoto J; Omura T; Sakaguchi T; Kimura N; Ohtaki K; Ono T; Suno M; Asari M; Ohkubo T; Noda T; Awaya T; Shimizu K; Matsubara K
Neurosci Lett; 2012 Jul; 521(1):15-9. PubMed ID: 22617635
[TBL] [Abstract][Full Text] [Related]
40. Protective role of 6-Hydroxy-1-H-Indazole in an MPTP-induced mouse model of Parkinson's disease.
Xiao-Feng L; Wen-Ting Z; Yuan-Yuan X; Chong-Fa L; Lu Z; Jin-Jun R; Wen-Ya W
Eur J Pharmacol; 2016 Nov; 791():348-354. PubMed ID: 27614126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
